MEDRAD Builds on Success of P3T Cardiac CT Injectio...( WARRENDALE Pa. Nov. 24 /- Encouraged ...),Health

WARRENDALE, Pa., Nov. 24 /PRNewswire/ -- Encouraged by successful results from use of its patented personalized patient protocol software P3T(TM) Cardiac, MEDRAD, Inc. is working on advancing the P3T family of products for clinical applications beyond Cardiac CT. MEDRAD will demonstrate some of these potential advances at its RSNA Booth 2815 Hall A, South Building.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

Personalized patient injection protocols are showing promise, according to a recent University of Pittsburgh Medical Center (UPMC) study(1) which documented that contrast injection protocols personalized to patient-specific parameters of its test group resulted in a higher percentage of exams that could be classified as "diagnostic, without limitations" to rule out pulmonary embolism than resulted from non-personalized standard injection protocols.(2) A diagnostic exam without limitations is the type that is most desired by radiologists. The personalized patient protocols provided better contrast enhancement of the pulmonary arteries in the study group as well.(2) Researchers presented the study results in a scientific poster at a meeting of the Society of Thoracic Radiology earlier this year. Copies of the study will be available at MEDRAD's booth at the RSNA 2008 exhibition in Chicago, November 30 through December 5.

Joan Lacomis, radiologist at UPMC and co-author of the UPMC study, said, "Achieving a diagnostic CT image for pulmonary embolism, without limitations, helps the hospital and emergency department in a number of important ways -- with efficiency, patient care, and cost savings. Achieving high quality images for a higher percentage of studies multiplies these benefits and our research indicates that personalizing the contrast injection protocol to patient-specific parame
'/>"/>